<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897881</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-4157-P201</org_study_id>
    <nct_id>NCT03897881</nct_id>
  </id_info>
  <brief_title>An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942)</brief_title>
  <official_title>A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157
      and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in
      patients with complete resection of cutaneous melanoma and a high risk of recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>RFS is defined as the time between the date of first dose of pembrolizumab and the date of recurrence (local, regional, or distant metastasis), new primary melanoma, or death (whatever the cause), whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival (DMFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>DMFS is defined as the time between the date of first dose of pembrolizumab and the date of the first distant metastasis or the date of death (whatever the cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events (AEs)</measure>
    <time_frame>Baseline through 90 days after last pembrolizumab dose</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations due to AEs</measure>
    <time_frame>Baseline through 90 days after last pembrolizumab dose</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS is defined as the time between the date of first dose of pembrolizumab and the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Combination treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-4157 and pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-4157</intervention_name>
    <description>Personalized cancer vaccine</description>
    <arm_group_label>Combination treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Combination treatment arm</arm_group_label>
    <arm_group_label>Control treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable cutaneous melanoma metastatic to a lymph node and at high risk of
             recurrence

          -  Complete resection within 13 weeks before study enrollment

          -  Disease free at study entry (after surgery) with no loco-regional relapse or distant
             metastasis and no clinical evidence of brain metastases

          -  Has an FFPE tumor sample available suitable for sequencing

          -  ECOG Performance Status 0 or 1

          -  Normal organ and marrow function reported at screening

        Exclusion Criteria:

          -  Prior malignancy, unless no evidence of that disease for at least 5 years prior to
             study entry

          -  Prior systemic anti-cancer treatment (except surgery and interferon for thick primary
             melamonas. Radiotherapy after lymph node dissection is permitted)

          -  Live vaccine within 30 days prior to the first dose of pembrolizumab

          -  Transfusion of blood or administration of colony stimulating factors within 2 weeks of
             the screening blood sample

          -  Active autoimmune disease

          -  Immunodeficiency, systemic steroid therapy or any other immunosuppressive therapy
             within 7 days prior to the first dose of pembrolizumab

          -  Solid organ or allogeneic bone marrow transplant

          -  Pneumonitis or a history of (noninfectious) pneumonitis that required steroids

          -  Prior interstitial lung disease

          -  Clinically significant heart failure

          -  Known history of HIV

          -  Known active hepatitis B or C

          -  Active infection requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>855-663-6762</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute -CPMCRI</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Kim, MD</last_name>
      <phone>415-885-8600</phone>
      <email>kimkb@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Faries, MD</last_name>
      <phone>310-582-7020</phone>
      <email>mfaries@theangelesclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Lewis, MD</last_name>
      <phone>720-848-0637</phone>
      <email>karl.lewis@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Weiss, MD</last_name>
      <phone>203-785-6378</phone>
      <email>sarah.weiss.sw842@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Gibney, MD</last_name>
      <phone>813-745-3437</phone>
      <email>geoffrey.t.gibney@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI Florida Cancer Specialists East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Rothschild, MD</last_name>
      <phone>561-366-4131</phone>
      <email>nrothschild@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Sullivan, MD</last_name>
      <phone>617-632-5470</phone>
      <email>rsullivan7@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonel Hernandez Aya, MD</last_name>
      <phone>314-747-7510</phone>
      <email>lhernand@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Pecora, MD</last_name>
      <phone>551-996-5814</phone>
      <email>andrew.pecora@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Weber, MD</last_name>
      <phone>212-731-6262</phone>
      <email>jeffrey.weber@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Taylor, MD</last_name>
      <phone>503-494-8534</phone>
      <email>taylmatt@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith McKean, MD</last_name>
      <phone>615-329-7274</phone>
      <email>mmckean@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Cowey, MD</last_name>
      <phone>214-370-1000</phone>
      <email>lance.cowey@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Carlino, MD</last_name>
      <phone>+61 2 9845 5200</phone>
      <email>matteo.carlino@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Atkinson, MD</last_name>
      <phone>+61 7 3176 3091</phone>
      <email>victoria.atkinson@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital Subiaco</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Khattak, MD</last_name>
      <phone>+61 8 6102 3640</phone>
      <email>Muhammad.Khattak@health.wa.gov.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-4157</keyword>
  <keyword>Personalized cancer vaccine</keyword>
  <keyword>PCV</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Moderna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

